Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Baxter gets exclusive rights to Merrimack's late-stage pancreatic cancer candidate MM398

Executive Summary

Merrimack Pharmaceuticals Inc. (oncology drug development) granted Baxter International Inc. exclusive worldwide rights to sell its MM398 for patients with pancreatic cancer who have already been treated with gemcitabine. The deal excludes the US, where Merrimack retains rights, and Taiwan, where PharmaEngine already holds a license.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Liposomes
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies